大学ホーム医学研究科教育・研究指導教員紹介:桶川 隆嗣

教員紹介:桶川 隆嗣


項目名 内容
氏名 桶川 隆嗣
フリガナ オケガワ タカツグ
職位 教授
所属教室
専攻・専門分野
 (大学院)
担当科目(学部) 泌尿器科学
担当科目(大学院) 泌尿器科学演習、泌尿器腫瘍学
専門分野 泌尿器腫瘍学、腹腔鏡・ロボット手術、分子生物学
研究テーマ 1.Liquid Biopsy (CTC, cfDNA, exosome)の臨床的応用(遺伝子解析)
2.腎癌におけるメタボローム解析
3.泌尿器科癌におけるオーファン核内受容体の発現に関する研究
4.去勢抵抗性前立腺癌となるメカニズムの解明
5.尿路・生殖器系腫瘍におけるアデノウイルスレセプターを用いた遺伝子治療の開発
略歴 1998年 杏林大学大学院医学研究科卒業
1999年 米国テキサス大学(サウスウェスタンメディカルセンター) 泌尿器科 (腫瘍学研究員)
2001年 杏林大学医学部泌尿器科講師
2004年 杏林大学医学部泌尿器科助教授(准教授)
2014年 杏林大学医学部泌尿器科教授
所有する学位 博士(医学)
指導医・専門医・認定医、その他の資格等 日本泌尿器科学会:専門医・指導医、泌尿器腹腔鏡技術認定医、日本内視鏡外科学会技術認定医、癌治療認定医・暫定教育医、大学間共用試験実施評価機構 医学系OSCE評価者認定医
論文・著書等を含む主要研究業績 First authorのみ記載
1. Okegawa T, et al. Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors. EBioMedicine. 2017 May;19:31-38.
2. Okegawa T, et al. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.Int J Mol Sci. 2016 Nov 30;17(12). pii: E2008.
3. Okegawa T, et al. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration resistant prostate cancer. Anticancer Res. 2014;34(11):6705-10.
4. Okegawa T, et al. Bone Metastasis Prostate Cancer Group. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naïve prostate cancer in a multicenter clinical trial. Anticancer Res. 2014;34(8):4415-20.
5. Okegawa T, et al. Orphan nuclear receptor HNF4G promotes bladder cancer growth and invasion through the regulation of the hyaluronan synthase 2 gene. Oncogenesis.2013 29;2:e58. doi: 10.1038/oncsis.2013.25
6.Okegawa T, Iet al.Retroperitoneal laparoscopic single-site nephroureterectomy: Initial operative experience. Asian J Endosc Surg 5(4):164-7, 2012.
7.Okegawa T, et al. Initial operative experience of single-port retroperitoneal laparoscopic nephrectomy. Int J Urol.2012.
8.Okegawa T, et al. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: A single-center experience. Int J Urol 17:950-955,2010.
9.Okegawa T, et al.Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. Int J Urol 17:466-475,2010.
10.Okegawa T, et al.Comparison of laparoscopic and open adrenalectomy for pheochromocytoma in a single center. Asian J Endosc Surg、3,145-149,2010.
11.Okegawa T, et al. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int J Urol 17:254-258,2010.
12.Okegawa T, et al. Prognostic Significance of Circulating Tumor Cells in Patients With Hormone Refractory Prostate Cancer.J Urol 181:1091-1097, 2009.
13.Okegawa T, et al. Comparison of transperitoneal and retroperitoneal laparoscopic nephrectomy for renal cell carcinoma: a single-center experience of 100 cases. Int J Urol 15(11):957-60,2008.
14.Okegawa T, et al. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate
cancer.J Urol. 2008;180(4):1342-7.
15.Okegawa T, et al. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells. J Urol 77(3):1148-1156,2007.
16.Okegawa T, et al. Oncological outcome of retroperitoneoscopic nephroureterectomy for upper urinary tract transitional cell carcinoma. Int J Urol 13:493-7, 2006.
17.Okegawa T, et al. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy. Int J Urol 13:1197-201, 2006.
18.Okegawa T, et al. Laparoscopic management of urachal remnants in adulthood. Int J Urol 13,1466-1469,2006.
19. Okegawa T, et al.Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor. J Urol 174, 747-752, 2005.
20. Okegawa T, et al. Value of reverse transcription polymerase chain assay in peripheral blood of patients with urothelial cancer. J Urol. 171(4):1461-1466. 2004.
21. Okegawa T, et al. Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng/ml. Int J Urol 10,201-206,2003.
22. Okegawa T, et al. Detection of mucin 7 gene expression in exfoliated cells in urine from patients with bladder tumor. Urology 62: 182-186,2003.
23.Okegawa T, et al. The prognostic value of 3 molecular forms of prostate specific antigen ratios in patients with adenocarcinoma of the prostate. Urology57(5):936-942,2001.
24.Okegawa T, et altigen as predictors of the pathological stage of prostate cancer. Int J Urol 8(8):438-443, 2001.
25.Okegawa T, et al. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: A functional analysis of CAR proteins structure. Cancer Res 61(17):6592-6600,2001.
26. Okegawa T, et al. Comparisons of the various combinations of free, complexed, and total prostate-specific antigen for the detection of prostate cancer. Eur Urol 38(4): 380-387,2000.
27. Okegawa T, et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 60(18): 5031-5036,2000.
28. Okegawa T, et al. Value of reverse transcription polymerase chain reaction assay in pathological stage T3N0 prostate cancer. Prostate 44(3): 210-218,2000.
29. Okegawa T, et al. Comparison of two investigative assays for the complexed prostate-specific antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology 55(5): 700-704, 2000.
30. Okegawa T, et al. The significance of the free-to-complexed prostate-specific antigen (PSA) ratio in prostate cancer detection in patients with a PSA level of 4.1-10.0 ng/mL. BJU Int 85(6):708-714,2000.
31. Okegawa T, et al. Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer. J Urol 163(4):1183-1188,2000.
32.Okegawa T, et al. Preoperative nested reverse transcription-polymerase chain reaction for prostate specific membrane antigen predicts biochemical recurrence after radical prostatectomy. BJU Int 84(1):112-117,1999.
33.Okegawa T, et al. Molecular staging of prostate cancer: comparison of nested reverse transcription polymerase chain reaction assay using prostate specific antigen versus prostate specific membrane antigen as primer. Int J Urol 5(4): 349-356,1998.
所属学会 日本泌尿器科学会(代議員)、日本泌尿器内視鏡学会(代議員)、日本ロボット外科学会、日本癌学会、日本癌治療学会、日本内視鏡外科学会、日本排尿機能学会、日本抗加齢医学会
公的な委員会等の役員・委員歴 泌尿器内視鏡学会保険委員、泌尿器内視鏡編集委員
International Cancer Conference Journal(ICCJ)
Board Member
ひとことメッセージ 患者さんに負担の少ない低浸襲性手術(ロボット支援手術、腹腔鏡下手術、小線源療法など)を専門としています。
付属病院ホームページ ドクター紹介(2015年02月24日公開)
このページのトップへ

PAGE TOP